ImmunityBio, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.09 | $-0.08 | +11.1% | Beat |
| Q12026 FY2026 | $-0.08 | $-0.09 | -12.5% | Miss |
| Q42025 FY2025 | $-0.08 | $-0.06 | +25.0% | Beat |
Back to IBRX overview · IBRX holders · IBRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.